Fas peptides and antibodies for modulating apoptosis

Details Fas peptides and antibodies for modulating apoptosis Fas peptides and antibodies for modulating apoptosis

2005-01-25

2005-01-25

Harris, Alana M. (Department: 1642)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

C435S004000, C424S130100, C424S140100, C436S536000, C514S001000, C514S002600, C514S013800, C514S015800, C530S300000, C530S350000

Reexamination Certificate

active

06846637

ABSTRACT:
Anti-Fas (APO-1, CD95) autoantibodies arm found in human s, which antibodies arm biologically functional. Peptide fragments of Fas recognized by such antibodies, and antibodies specific for such peptides, inhibit or promote apoptosis and cellular proliferation. Assay methods making use of Fas peptides or antibodies enable identification of further agents which modulate apoptosis and/or cellular proliferation.

REFERENCES:
patent: 5620889 (1997-04-01), Lynch et al.
patent: 5652210 (1997-07-01), Barr et al.
patent: 5663070 (1997-09-01), Barr et al.
patent: 5830469 (1998-11-01), Lynch et al.
patent: 5874546 (1999-02-01), Nagata et al.
patent: 5891434 (1999-04-01), Krammer et al.
patent: 6015559 (2000-01-01), Lynch et al.
patent: 6086877 (2000-07-01), Nishioka et al.
patent: 6270998 (2001-08-01), Nagata et al.
patent: 195 44 332 (1997-06-01), None
patent: 0 510 691 (1992-10-01), None
patent: 0 511 202 (1992-11-01), None
patent: 0 709 097 (1996-05-01), None
patent: 0 716 095 (1996-06-01), None
patent: 0 799 891 (1997-10-01), None
patent: 0 866 131 (1998-09-01), None
patent: 0 909 816 (1999-04-01), None
patent: 0 990 663 (2000-04-01), None
patent: 1180369 (2002-02-01), None
patent: 09 166593 (1997-06-01), None
patent: WO 9510540 (1995-04-01), None
patent: WO 9513701 (1995-05-01), None
patent: WO 9712632 (1997-04-01), None
patent: WO 9808965 (1998-03-01), None
G.C. Starling et al., “Identification of Amino Acid Residues Important for Ligand Binding to Fas”; J.Exp.Med—Brief Definitive Report, vol. 185, No. 8:1487-1492 (1997).
N. Prasad et al., “Therapeutic Preparations of Normal Polyspecific IgG (IVIg) Induce Apoptosis in Human Lymphocytes and Monocytes: A Novel Mechanism of Action of IVIg Involving the Fas Apoptotic Pathway”; The Journal of Immunology, 3781-3790 (1998).
I. Viard et al., “Inhibition of Toxic Epidermal Necrolysis by Blockade of CD95 with Human Intravenous Immunoglobulin”, Science, vol. 282:490-493 (1998).
B. Fadeel et al., “A three-dimensional model of the Fas/APO-1 molecule: cross-reactivity of anti-Fas antibodies explained by structural mimicry of antigenic sites”, International Immunology, vol. 10, No. 2:131-140 (1998).
B. Fadeel et al., “Anti-Fas IgG1 antibodies recognizing the same epitope of Fas/APO-1 mediate different biological effects in vitro”, International Immunology, vol. 9, No. 2:201-209 (1997).
B. Fadeel et al., “Mapping of the linear site on the Fas/APO-1 molecule targeted by the prototypic anti-Fas mAb”. International Immunology, vol. 7, No. 12:1967-1975 (1995).
Stricker, K., et al., “Anti-CD95 (APO-1/Fas) autoantibodies and T cell depletion in human immunodeficiency virus Type 1 (HIV-1)-infected children”, Cell Death and Differentiation, 5: 222-230, (1998).

Affiliated with

Also associated with

Rating

Fas peptides and antibodies for modulating apoptosis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Fas peptides and antibodies for modulating apoptosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fas peptides and antibodies for modulating apoptosis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3407876